Business
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative (“seronegative”) gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Am
About this update from Argenx Se
[{"type":"image","alt":"argenx SE","displaySize":"","headline":null,"caption":"argenx SE","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":97,"url":"https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_55.hEettGltaZ5cA.9xTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119","width":300,"height":97}},"lazy":false},{"type":"text","content":"$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth","length":125,"tagName":"p"},{"type":"text","content":"Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability","length":97,"tagName":"p"},{"type":"text","content":"VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative (“seronegative”) gMG ","length":174,"tagName":"p"},{"type":"text","content":"Management to host conference call today at 2:30 PM CET (8:30 AM ET)","length":68,"tagName":"p"},{"type":"text","content":"February 26, 2026 7:00 AM CET","length":29,"tagName":"p"},{"type":"text","content":"Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2025 and provided a fourth quarter business update.","length":283,"tagName":"p"},{"type":"text","content":"In a separate press release issued today, argenx announced positive results from the Phase 3 ADAPT OCULUS study evaluating VYVGART SC pre-filled syringe (PFS) for the treatment of adult patients living with ocular myasthenia gravis (oMG). The primary endpoint was met (p=0.012), demonstrating statistically significant improvement from baseline in Myasthenia Impairment Index (MGII) Patient Reported Outcome (PRO) ocular scores at Week 4 in treated patients compared to placebo. No new safety concerns were identified.","length":518,"tagName":"p"},{"type":"text","content":"“argenx delivered another standout year of execution in 2025,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “We reached 19,000 patients globally with VYVGART, ex...